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Background. Factor VII is a plasma glycoprotein that participates in the coagulation process leading to 
generation of fibrin. Construction, expression and purification of recombinant FVII fused to poly histidin 
tag through gateway technology were aimed in this study. 
Methods. To construct entry clone, blunt-end FVII cDNA and subsequent PCR product isolated from 
HepG2 cell line was TOPO cloned into pENTR TOPO vector.  To construct expression clone, LR 
recombination reaction was carried out between entry clone and destination vector, pDEST26. CHO cells 
were transfected with 1μg of DNA of PDEST26–FVII using the FuGENE HD transfection reagent. Two 
cell lines that permanently expressed recombinant factor VII were established. The expression of 
recombinant FVII was confirmed by RT-PCR and ELISA. Culture medium containing his-FVII was 
added to the nickel-nitrilotriacetic acid resin column and bound protein was eluted. The purified protein 
was detected by SDS-PAGE and western blot analysis. Biological activity of the recombinant factor VII 
was determined by prothrombin time assay using factor FVII-depleted plasma. 
Results. The results showed that human recombinant FVII successfully was cloned and accuracy of the 
nucleotide sequence of the gene and its frame in the vector were confirmed by DNA sequencing. Stable 
clones transfected with the construct expressed FVII mRNA and related protein but any expression was 
not detected in the CHO cells containing empty vector. A protein of about 52KDa was detected in SDS-
PAGE and was further confirmed by western blot analysis. A three-fold decrease in clotting time was 
observed by using this rFVII. 
Conclusion. As we are aware, this is the first report of expression of recombinant FVII fused with his-tag 
through gateway technology. The next steps including large scale expression, purification, activation and 
stabilization are underway. 
 Key words: Gateway technology, Hemophilia, Recombinant FVII, His-Tag, Purification 
Page 1 of 10 
Roudkenar  M H et al. 
Introduction 
Factor VII is a plasma glycoprotein that participates in the coagulation process leading to the generation 
of fibrin1,2. It is synthesized in the liver where vitamin K is required for the formation of approximately 10 
γ-carboxyglutamic acid residues that are present in the amino-terminal region of the protein2-4. Factor VII 
is a single-chain glycoprotein that is secreted into the blood and circulates in a zymogen form5-8. It is 
converted to factor VIIa by factor Xa7, 9, factor XIIa7,10-12, and factor IXa12 or thrombin9 through minor 
proteolysis. Activated FVII (FVIIa) initiates the extrinsic coagulation pathway by binding to tissue factor 
on the surface of cells that have become exposed to circulating blood following injury13,14. Recombinant 
human FVIIa can counterbalance the factor VIII (FVIII) or factor IX (FIX) deficiencies and could be used 
for treatment of bleeding in hemophilia A or B patients that produce antibodies (inhibitors) against FVIII 
or FIX13,15. Nowadays two different types of FVII preparation exist: plasma-derived and recombinant.  
Low yield and possible viral contamination are disadvantages of plasma-derived FVII. Commercially 
available FVIIa, NovoSeven, is produced in baby hamster kidney (BHK) cell line that secretes FVII into 
the culture medium in its single chain form. The product is purified with murine monoclonal anti-FVII 
antibodies and subsequent ion exchange chromatography further purifies the product. Because this type of 
purification is time-consuming and expensive, construction, expression and purification of recombinant 
FVII fused to poly histidin tag through gateway technology were aimed in this study. 
 
Materials and methods 
Plasmids and bacteria 
Plasmids pENTR TOPO/D and pDEST26 (Invitrogen, USA) were used in different stages of cloning and 
expression procedure. pENTR TOPO/D  was used for initial cloning and  sequencing. Bacterial strain E. 
coli DH5α (Invitrogen, Carlsbad, CA) was used as a host for cloning of the constructs. pDEST26 
expression vector provides the opportunity to clone the desired insert as a fusion protein with  N-terminal 
polyhistidine tag. This tag facilitates detection of the expressed protein with anti-his antibody and also 
purification of the protein using the metal-binding site for affinity purification of the recombinant protein. 
 
Cell culture 
HepG2 (human hepatoma cell line) and CHO (chinese hamster ovary cell line) were obtained from 
National Cell Bank of Iran (NCBI).  These cell lines were grown in RPMI-1640 medium (Gibco-BRL, 
Eggenstein, Germany) containing 10% fetal bovine serum, 1µg/mL vitamin K1, 100 U/mL penicillin, and 
100 µg/mL streptomycin. (Gibco-BRL, Eggenstein,Germany). 
 
Isolation of FVII cDNA and plasmid construction  
HepG2 cell line was used as a source of human FVII gene. Total RNA was extracted by Trizol reagent 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.  The quality of RNA was 
determined by electrophoresis. Reverse transcription was performed by SuperScript III reverse 
transcriptase (Invitrogen, USA) with 2µg of total RNA followed by DNaseI (Invitrogen, USA) treatment 
and heat inactivation.  Full length human FVII cDNA was isolated using specific primers by RT-PCR. 
PCR was performed using Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA) in a GeneAmp 
PCR system 9600 (PerkinElmer Life And Analytical Sciences, Inc., Wellesley, MA, USA).  After initial 
denaturation (5 min. at 94ºC), cDNA was subjected to 30 cycles of PCR.  Primer set for amplification of 
full length human FVII gene containing Kozak sequence site included forward: 5’-ACCATGGTG GTC 
TCC CAG GCC CTC AGG CTC -3’ and reverse: 5’-T AGG GAA ATG GGG CTC GCA G -3’. PCR 
annealing temperature was 60º C for human FVII gene. PCR products were separated in 2 % agarose gel.  
Then the blunt-end PCR products were TOPO cloned into pENTR TOPO/D vector according to the 
manufacturer’s protocol (Invitrogen, USA). The reaction mixture was incubated for 5 minutes at room 
temperature. 
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Then the reaction was placed on ice and pENTR TOPO/D-FVII construct was transformed to competent 
E.coli according to the manufacturer’s protocol (Invitrogen, USA). Positive clones were selected on LB 
medium containing 100 µg/mL kanamycin. Plasmid DNA was isolated using high pure plasmid extraction 
kit (Roche, Germany). Presence of the insert was confirmed by PCR and finally to confirm the fidelity of 
the sequence, DNA sequencing was performed. This construct is called entry clone. Then, LR 
recombination reaction was carried out between entry clone and destination vector, pDEST26, according 
to manufacturer’s instruction (Invitrogen, Carlsbad, CA). The products of LR recombination were 
transformed to competent E.coli according to the manufacturer’s protocols. Positive clones were analyzed 
by culturing them on LB medium containing 100 µg/mL ampicillin and 30µg/mL chloromphenicol.  
Afterwards, the plasmid DNA was isolated using a commercially available plasmid extraction kit and was 
further analyzed by restriction enzyme digestion and PCR.  Finally this expression vector was transfected 
into CHO cell line. 
 
Transfection and generation of stable FVII-expressing cells 
CHO cells (5 ×105) were seeded and upon reaching 70% confluence were transfected with 1μg of 
pDEST26–FVII DNA using the FuGENE HD transfection reagent (Roche, Mannheim, Germany) 
according to the manufacturer’s protocol. pDEST26 DNA was used as a control. CHO cells containing 
pDEST26-FVII construct were selected in a medium containing 600 μg/mL geneticin (Roche, Mannheim, 
Germany) for at least 14 days.  Several stable clones were generated by dilution of the cells followed by 
their cultivation in 96 well culture plates. The expression of FVII was proved by RT-PCR and ELISA 
(Diagnostica Stago, France) according to the manufacturer’s protocol. 
 
Purification of polyhistidine-tagged FVII fusion protein and its characterization    
The FVII encoded by pDEST26 carries six histidine residues at its N terminus. Polyhistidine has a high 
affinity for a nickel-nitrilotriacetic acid resin permitting single-step purification of the fusion protein. The 
nickel-nitrilotriacetic acid resin was washed and culture medium containing FVII was added to the 
column, and bound protein was eluted according to the manufacturer’s instruction (Invitrogen, Carlsbad, CA).  
 
Detection of the purified protein 
The protein concentration was quantified by Bio-Rad protein assay kit according to the instructions of the 
supplier (Bio-Rad, USA). Purified protein was detected by running the samples heated in 1x SDS-PAGE 
sample buffer at 95 ο C for 5 min on 12% gels followed by Coomassie blue staining. The proteins were 
also blotted onto PVDF paper (Hi-bond Amersham Biosciences, USA) and blocked with a solution 
containing 5 % skimmed milk and 0.1% Tween 20. The blocked membranes were washed with PBS 
containing 0.05% Tween 20 and incubated with horseradish peroxidase-conjugated His antibody 
according to the instructions of the supplier (Roche, Mannheim, Germany) at room temperature for 1 h.  
Afterwards, the membranes were washed 4 times with PBS containing 0.1 % Tween 20, and finally the 
membranes were developed with DAB solution (Sigma, Dusseldorf, Germany).  Purified protein was also 
detected using goat anti-human coagulation factor VII antibody (R & D Systems, Minneapolis, MN)  with 
0.75 µg/mL peroxidase conjugated  anti-goat IgG (Dako, Denmark) as the secondary antibody. The 
coagulant activity of purified rFVII was measured using FVII-depleted human plasma (Diagnostica Stago, 
France ). Thromboplastin preparations utilized in the assay were from human (Hoechst Canada Inc., 
Behring Diagnostics, Montreal, Quebec, Canada).  PT assays were performed using fibrin timer cups and 
a mechanical fibrometer with a built-in automatic timer device (BBL, Division of Bioquest, Cockeysville, 
MD, USA). 
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Results  
Isolation and construction of the recombinant vectors 
Summary of the experiment is depicted in Figure 1. Specific primers were designed to amplify full length 
of human factor VII gene. The expected size of the PCR product was about 1400 bp. The blunt-end FVII 
PCR product was directly TOPO cloned into pENTR TOPO/D vector and the accuracy of the nucleotide 
sequence of the gene and its frame in the vector were confirmed by DNA sequencing (the gene is 
accessible in the gene bank with accession number EU557239). Next, to construct expression clone LR 
recombinant reaction was carried out between pENTR TOPO/D-FVII and pDEST26 vector.  
 
 
Figure 1 - A; Summary of construction of the entry and expression clones. HepG2 cell line was used as a source of FVII 
cDNA. Blunt-end PCR product was TOPO cloned into pENTR TOPO/D vector. The construct was used to transform 
competent E.coli and positive clones were selected on LB medium containing a proper antibiotic. This construct is called entry 
clone. Next, LR recombinant reaction was carried out between pENTR TOPO/D-FVII and pDEST26 vector to construct 
expression clone. The resulted pDEST26-FVII which is called expression clone was transfected into CHO cells. Stable clones 
expressing recombinant FVII were established in the presence of geneticin. B; pDEST26 vector. C; N-terminal sequence of the 
fusion protein.  
 
To check the putative expression clones, they were grown in the presence of chloramphenicol and the 
desired clones which were ampicillin-resistant and chloramphenicol-sensitive were chosen for further 
analysis using PCR, which proved the existence of the insert. Finally, to confirm that the FVII gene is in 
frame with appropriate tag, DNA sequencing was performed. Figure 1 – letter C represents the N-terminal 
sequence of the construct and its frame in detail. 
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Expression of FVII by CHO cell line 
To investigate whether pDEST26-FVII transfected cells express human FVII, RT-PCR was performed.  
Stable clones transfected with the construct expressed FVII mRNA but there was not any expression in 
the CHO cells transfected with pDEST26 vector (Figure 2).  The cell culture medium of stably pDEST26-
FVII transfected cells was used for detection of FVII protein by ELISA. The cells transfected with 
pDEST26-FVII expressed FVII protein while cells transfected with pDEST26 vector not (Figure 3). 
About 40% of His-FVII was found to be intracellular and not secreted to the medium. In another study, in 
which the FVII gene was cloned into pcDNA3.1 expression vector, which lacks a his-tag, the intracellular 




Figure 2 - Expression of the rFVII by stable clones of CHO. RNA was extracted from the CHO cells transfected with the 
pDEST26-FVII construct and the CHO cells transfected with the empty vector. cDNA was synthesized and RT-PCR was 
performed. CHO cells transfected with the construct expressed FVII mRNA, an approximately 1400 bp length fragment (Lane 
2), while in CHO cells transfected with empty vector any expression was not observed (Lane 1). Lower figure shows the 
expression of β-actin in both stable clones of CHO, i.e. transfected with the pDEST26-FVII or empty vector. M: 100 bp ladder 
marker. 
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Figure 3 - Detection of rFVII by ELISA. Cell culture medium and lysate of the stable clones were evaluated. The expression 
of rFVII was confirmed by ELISA.  His-FVII was detected both in cell culture medium and cell lysate. Two stable clones 
(Clone 1 and 2), CHO transfected with pcDNA 3.1-FVII and empty vector are shown in the figure. Any FVII expression was 
not detected in the medium of CHO cells transfected with empty vector (pcDEST26 3.1). Data are presented as mean ± SD. 
 
Purification and characterization of the expressed rFVII 
The recombinant fusion protein was purified using a nickel–sepharose column and eluted protein was 
analyzed by SDS-PAGE and western blotting. An approximately 52KDa protein was detected in SDS-
PAGE (Figure 4, letter A) which was further confirmed by western blot analysis using both anti-his and 
anti-FVII antibodies (Figure 4 letter B and letter C). 500 ng/mL of recombinant fusion His-FVII protein 
was obtained from 10 mL culture medium. To test whether the purified protein is biologically active, 
prothrombin time test was carried out.  
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Figure 4 - SDS-PAGE and Western blot analysis of recombinant FVII fusion protein. A; SDS-PAGE analysis. The 
recombinant fusion protein was purified using a nickel–sepharose column. After purification, a single protein band was 
detected in 12% SDS-PAGE (Lane 2). The cell culture medium of CHO cells transfected with empty vector was also passed 
through nickel–sepharose column. However, any band was not observed (Lane 1).  B; western blot analysis of eluted protein 
using anti-his-tag and anti-FVII antibodies (C). Eluted protein reacted with both antibodies, visualized by developing using 
DAB solution.  
 
A three-fold decrease in clotting time was observed when human FVII-depleted plasma was used in 
combination with human thromboplastin and the rFVII produced in this study. Similar results were 
observed when prepared his-tag free recombinant FVII, expressed using pcDNA3.1 expression vector and 
also a commercially available FVII ,NovoSeven, were used (Figure 5). 
 Taken together, this confirms the biological activity of the expressed His-rFVII and the fact that its 




Fig 5 - Prothrombin time assay. Biological activity of the purified recombinant his-FVII was evaluated by prothrombin time 
test.  A three-fold decrease in clotting time was observed when human FVII-depleted plasma was used in combination with 
human thromboplastin and the his-rFVII produced in this study.  About four-fold decrease in clotting time was also observed 
when a commercially available preparation of rFVII, NovoSeven, was used. The experiment was performed in triplicate and 
the Data are presented as mean ± SD. 
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Discussion 
In this study, for the first time we reported expression and purification of human recombinant FVII fused 
to his-tag. The gateway technology was employed for construction of the recombinant vectors. Gateway 
technology is a universal cloning method based on the site-specific recombination properties of lambda 
bacteriophage16. This technology provides a rapid and highly efficient way to clone DNA sequences into 
multiple vector systems for functional analysis and protein expression17. Briefly, in this technology there 
are two types of vectors. One is entry vector and other is destination or expression vector and accordingly 
there are two type of clones i.e. entry and expression.  In the present study, pENTR TOPO/D and 
pDEST26 were entry and expression vectors, respectively. PCR product, FVII cDNA, was directly TOPO 
cloned into pENTR TOPO/D vector during 5 minutes with 100% efficiency, and with no ligase, post-PCR 
procedures, or restriction enzymes required. pDEST26 vector was used as expression vector. During LR 
recombination between pENTR TOPO/D-FVII and pDEST26, FVII gene was inserted into the destination 
vector resulted in construction of pDEST26-FVII which was in frame with appropriate his-tag as 
determined by DNA sequencing. CHO cell line was used as a host for expression of recombinant FVII 
protein. Kemball-Cook et al also expressed recombinant FVII in CHO cell line. However, they used 
different vector, pNeoIG502, compared to ours i.e. pDEST26.   
For transfection of the construct into CHO cells they utilized electroporation while in the present study 
FuGENE HD  transfection reagent was used18. Simple methodology, minimal optimization, low 
cytotoxicity and ability to provide high transfection efficiency even in the presence of serum are 
advantages of FuGENE HD transfection reagent. Expression of recombinant rabbit FVII has been 
reported by Ruiz et al. They utilized pCMV5 for cloning and expression of rabbit recombinant FVII in 
human 293 cell line19. Rabbit rFVII was purified using a variation of the barium citrate precipitation 
technique followed by DEAE sepharose FF and benzamidine agarose column chromatography 19,20. 
Commercially available activated recombinant human coagulation factor VII (rFVIIa) or NovoSeven is 
produced in baby hamster kidney (BHK) cells and is purified by consecutive chromatography steps, 
including immunoaffinity chromatography using murine monoclonal antibodies. 
In our study, the rFVII encoded by pDEST26 carries six histidine residues at its N- terminus. 
Polyhistidine has high affinity for a nickel-nitrilotriacetic acid resin permitting single-step and fast (in 
about 1.5 hr) purification of recombinant FVII protein. This recombinant FVII protein was detected as a 
single band in SDS-PAGE and western blot analysis indicating high purity of the protein, obviating 
additional purification steps.  
Considering the fact that FVII is a secretion glycoprotein and its signal peptide recognition by SRP is 
essential for entering into the ER lumen, this question might raise that how his tag  remains in fusion 
protein? In other words, is the signal peptide removed?    Several hypothesis can be suggested to address 
this question including 1, The fusion protein unspecifically enters into ER which means without the 
involvement of SRP, 2, the protein is recognized by SRP and enters into ER but signal peptide is not 
removed by signal peptidase and 3, some part of protein enters into ER normally in which signal peptide 
is removed and others go through either the first or second mentioned pathways. However, further and 
complementary studies are required to clarify the precise mechanism in this regard. The results clearly 
confirm the existence of the his-FVII fusion protein in the cell culture medium as determined following 
elution using Ni++ column, SDS-PAGE and western blot analysis using both anti-his and anti-FVII 
antibodies. It is noteworthy that any rFVII protein was not detected in the culture medium of CHO cells 
producing his-tag free rFVII by expression of a pcDNA3.1 vector following passage of the medium 
through Ni++ column (data not shown), which proves the specific elution of His-FVII. However, 
Intracellular accumulation of His-FVII expressed by pDEST26 vector was much more higher compared to 
his tag free recombinant FVII expressed by pcDNA 3.1.  This indicates that the fusion of FVII to his-tag 
might impair its secretion.  
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Finally, a three-fold decrease in clotting time induced by rFVII was observed, indicating that the rFVII 
produced in this study was biologically active and its function was not affected by fusion. However, 
because of the cultivation of CHO cells in serum containing medium, the contamination of the purified 
FVII protein with FBS is possible. Thus, in later clinical studies and uses the application of serum-free 
mediums should be considered to overcome this problem.  
 
Conclusion 
As we are aware, this is the first report of expression of a recombinant FVII fused with his-tag through 
gateway technology. Our results revealed that the recombinant hybrid protein was biologically active. 
Simple methodology, minimal optimization, high efficiency, low costs and fast procedure might be the 
advantages of our study.  The next steps including large scale expression, purification, activation and 
stabilization are underway. 
 
Acknowledgments 
We thank Mr.  Mehdi Tabrizi for his help in manuscript preparation. 
 
References 
1) Davie EW, Fujikawa K, Kurachi K, Kisiel W. The role of serine proteases in the blood coagulation 
cascade. Adv Enzymol Relat Areas Mol Biol 1979; 48: 277-318. 
2) Frederick SH, Charles LG, Patrick O, et al. Characterization of a cdna coding for human factor VII 
(blood coagulation/DNA sequence/vitamin k-dependent proteins). Proc. Nati. Acad. Sci. USA 1986; 
83: 2412-2416. 
3) DiScipio RG, Hermodson MA, Yates SG, Davie EW. A comparison of human prothrombin, factor IX 
(Christmas factor), factor X (Stuart factor), and protein S. Biochemistry 1977; 16: 698-706. 
4) Rapaport SI, Aas K, Owren PA. The effect of glass upon the activity of the various plasma clotting 
factors. J. Clin. Invest 1955; 34: 9-19. 
5) Kisiel W, Davie EW. Isolation and characterization of bovine factor VII. Biochemistry 1975; 14: 
4928-4934. 
6) Radcliffe R, Nemerson Y. Activation and control of factor VII by activated factor X and 
thrombin.Isolation and characterization of a single chain form of factor VII. J Biol Chem 1975; 250: 
388-95. 
7) Miletich JP, Broze GJ, Majerus PW. The synthesis of sulfated dextran beads for isolation of human 
plasma coagulation factors II, IX, and X. Human factor VII. Methods Enzymol 1980; 105: 304-310. 
8) Bajaj SP, Rapaport SI, Brown SF.  Isolation and characterization of human factor VII. Activation of 
factor VII by factor Xa. J Biol Chem 1981; 256: 253-9. 
9) Radcliffe R, Nemerson Y. Mechanism of activation of bovine factor VII. Products of cleavage by 
factor Xa. J Biol Chem 1976; 251: 4749-802. 
10) Kisiel W, Fujikawa  K, Davie EW.  Activation of bovine factor VII (proconvertin) by factor XIIa 
(activated Hageman factor). Biochemistry 1977; 19: 4189-4194. 
11) Radcliffe R, Bagdasarian S, Colman R, NemersonY. Activation of bovine factor VII by hageman 
factor fragments. Blood 1977; 50: 611-617. 
12) Seligsohn U, Osterud B, Brown SF, et al.  Activation of human factor VII in plasma and in purified 
systems: roles of activated factor IX, kallikrein, and activated factor XII. J Clin Invest 1979; 64: 1056-
1065.  
13) Bolt G, Kristensen C,  Dock TS. Posttranslational N-glycosylation takes place during the normal 
processing of human coagulation factor VII. Glycobiology 2005; 15: 541-547.  
14) Rapaport SI, Rao LV. Initiation and regulation of tissue factor-dependent blood coagulation. 
Arterioscler. Throm 1992; 12: 1111-1121. 
Page 9 of 10 
Roudkenar  M H et al. 
15) Astermark J. Treatment of the bleeding inhibitor patient. Semin Thromb Haemost 2003; 29: 77-85. 
16) Landy A. Dynamic, Structural, and Regulatory Aspects of Lambda Site-specific Recombination. Ann. 
Rev. Biochem 1989; 58: 913-949. 
17) Hartley JL, Temple GF, Brasch MA. DNA Cloning Using in vitro Site-Specific Recombination. 
Genome Research 2000; 10: 1788-1795. 
18) Kemball CG, Garner I , Imanaka Y, et al. High-level production of human blood coagulation factors 
VII and XI using a new mammalian expression vector. Gene 1994; 139: 275-279. 
19) Ruiz1 SM, Sridhara1 S, Blajchman MA, Clarke BJ. Expression and Purification of Recombinant 
Rabbit Factor VII. Thrombosis Research 2000; 98: 203-211. 
20) Clarke BJ, Ruiz S, Sridhara S, Blajchman MA. Yolk antibodies against a conserved mammalian 





Corresponding author: Mehryar Habibi Roudkenar 
Research Center, Iranian Blood Transfusion Organization 
Tehran, Iran 
E-mail: Roudkenar@ibto.ir 
Page 10 of 10 
